Spring has spung, and so has March’s edition of The Radiology Rundown.
It’s been a month filled with lots of new updates, along with plenty more conferences and events in the world of radiology and the wider medical imaging space.
FDA Approvals
Subtle Medical announced CE mark for their SubtleHD product. Expect to see them making a big impact in Europe this year.
Intrasense also achieved CE mark for their AI solution for the detection of bone lesions on CT scan images, co-developed with Guerbert.
Gleamer also had a successful month for market approvals, with Chestview achieving FDA clearance for CADe.
Funding Updates
UK based Brainomix announced they had secured £4m Series C investment in the stroke AI space. This investment will help accelerate their commercial expansion into the USA.
Radiobotics were awarded just shy of £500,000 from SBRI Healthcare, as part of their Competition 26 (Urgent & Emergency Care) funding competition.
In the world of Digital Pathology AI, Proscia secured a huge $50m funding, taking their total raised to $130m. A great talking point for their team heading into USCAP no doubt.
Partnerships & Acquisitions
NVIDIA were at the heart of several partnerships in medical imaging this month, announcing partnerships with GE Healthcare, Subtle Medical and Hyperfine. Expect to see NVIDIA and medical imaging become an ever more common link heading into 2026.
Other key partnerships and collaborations announced this month:
➡️ Gleamer X Pixyl
➡️ Riverain X CARPL
➡️ Contextflow X Mint Medical
➡️ Iber X Philips
➡️ Cerebriu X CARPL
Want The Radiology Rundown delivered straight to our inbox?
Join The Radiology Rundown community and register your details to receive The Radiology Rundown directly to your inbox via the form here.